老美国印第安人的算法定义记忆障碍:强壮的心脏研究
Astrid M Suchy-Dicey1, Thomas Grabowski2, Dedra Buchwald2
1Huntington Medical Research Institutes.
Neuropsychology
|July 8, 2024
概括
使用加利福尼亚州口头学习测试II-Short Form (CVLT-SF) 的算法在美国印第安人中发现了记忆缺陷. 虽然准确度中等,但为了最佳的痴呆病例识别,需要进一步细化.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 公共卫生 公共卫生
背景情况:
- 美国印第安人的认知评估面临重大挑战,包括医疗保健准入障碍和未经验证的临床标准.
- 算法方法为识别认知障碍提供了一个有希望的替代方案,在某些情况下可能超过临床判断.
研究的目的:
- 开发和评估一种算法方法,使用单个认知测试对美洲印第安人的记忆缺陷进行分类.
- 评估这个算法的性能与痴呆症诊断的黄金标准相比.
主要方法:
- 加利福尼亚州口头学习测试II-简单表格 (CVLT-SF) 和临床数据是在2010-2013年从818名美洲印第安人 (65-95岁) 收集的,并于2017-2019年进行了后续调查.
- 一个算法将CVLT-SF得分分为四个记忆缺陷类别:没有,编码,存储和检索.
- 痴呆症的诊断是通过协商一致的裁决来确定的.
主要成果:
- 在基线时,在24.6%的参与者中观察到记忆缺陷 (15.6%的编码,3.5%的存储,5.5%的检索).
- 在随访时,大量初始缺陷的参与者消失了,大多数新缺陷出现在以前没有受损的个体中.
- 该算法在分类痴呆症方面表现出适度的准确性 (69%的正确性,51%的灵敏性,91%的特异性).
结论:
- 这项研究提出了一种新的方法,用单一的认知测试来定义美洲印第安人的记忆障碍.
- 需要进一步的研究来提高算法的灵敏度和实用性,以识别这一群体的认知障碍.
- 这些发现代表了改善认知评估和对未经研究的群体进行痴呆症护理的关键进展.
更多相关视频
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.1K
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
7.3K
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35